Mainz Biomed B.V. announced a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz's flagship product, a highly efficacious and easy to use at-home detection test for colorectal cancer (CRC). Dante Labs is a global leader in genome sequencing with a product development and commercial franchise focused on providing personalized preventive healthcare solutions by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to consumers and healthcare professionals.

Inherent to Dante Lab's business model is managing genomic sequencing laboratories in multiple international regions, and operating a robust e-commerce platform. The partnership will first launch ColoAlert in Italy and UAE using Dante's various established commercial channels. Samples will initially be processed at Mainz's in-house facility and then Dante will purchase Mainz's CE-IVD polymerase chain reaction (PCR) assay kits and transition all test processing to Dante's wholly-owned automated genomic sequencing laboratories in Italy (Europe) and Dubai (UAE) to offer localized service and support.

ColoAlert is currently marketed across Europe, and the partnership with Dante Labs marks the test's initial launch in the Middle East. Mainz will continue to develop commercial and R&D partnerships with companies that lead the field of health screening with a particular focus on stool diagnostics.